Abstract | BACKGROUND/AIM: METHODS: We conducted prospective analyses in the Endocrinology Clinic of the Pamukkale University. Acromegaly patients who had active disease participated in two admissions: before and after 6 weeks of daily treatment with 8 mg of oral rosiglitazone. Four male and 3 female patients have completed the study. Basal and nadir GH levels during an oral glucose tolerance test were determined, and the IGF-1 and IGF-binding protein-3 levels were also measured both before and 6 weeks after the rosiglitazone treatment. RESULTS: Treatment with rosigitazone did not reduce basal and nadir GH levels during the oral glucose tolerance test and the IGF-1 levels in the patient population as a whole (p > 0.05). CONCLUSIONS: The PPAR-gamma activator rosiglitazone, used at maximum approved dosage, did not reduce plasma GH and IGF-1 levels in patients with acromegaly. Further studies with higher doses and longer duration of PPAR-gamma agonist administration would be required to determine its usefulness in the treatment in this group of patients.
|
Authors | Mehmet Bastemir, Fulya Akin, Guzin Fidan Yaylali |
Journal | Neuroendocrinology
(Neuroendocrinology)
Vol. 86
Issue 2
Pg. 119-23
( 2007)
ISSN: 1423-0194 [Electronic] Switzerland |
PMID | 17671378
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | (c) 2007 S. Karger AG, Basel. |
Chemical References |
- Hypoglycemic Agents
- PPAR gamma
- Thiazolidinediones
- Rosiglitazone
- Human Growth Hormone
- Insulin-Like Growth Factor I
|
Topics |
- Acromegaly
(blood, drug therapy)
- Adenoma
(blood, drug therapy)
- Adult
- Diabetes Mellitus
(drug therapy)
- Female
- Growth Hormone-Secreting Pituitary Adenoma
(blood, drug therapy)
- Human Growth Hormone
(blood)
- Humans
- Hypoglycemic Agents
(administration & dosage)
- Insulin-Like Growth Factor I
(metabolism)
- Male
- Middle Aged
- PPAR gamma
(agonists, metabolism)
- Prospective Studies
- Rosiglitazone
- Thiazolidinediones
(administration & dosage)
- Treatment Failure
|